



Retrospective Analysis of Clinical Epidemiology in Gastrointestinal Stromal Tumour

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Clinical Oncology*

By

Mustafa Mohamed A. Azim Mohammed
M.B.B.Ch.

Under Supervision of

Prof. Amr Lotfy Farag

*Professor of Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University*

Dr. Mai Mohamed Ali Ezz El Din

*Assistant Professor of Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University*

Dr. Nesreen Ahmed Mosalam

*Assistant Professor of Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2018



وَمَنْ أَحْيَاهَا فَكَأَنَّمَا أَحْيَا النَّاسَ جَمِيعًا

And whoever saves one - it is as if he
had saved mankind entirely.

سورة المائدة - آية 32
Holy Quran - 5:32

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Amr Lotfy Farag**, Professor of Oncology and Nuclear Medicine, Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr/ Mai Mohammed Ali**, Assistant Professor of Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Mesreen Ahmed Mosalam**, Assistant Professor of Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I would like to express my hearty thanks to all **my family** for their support till this work was completed.*

Last but not least my sincere thanks and appreciation to all my colleagues who helped me in this study.

Mustafa A. Azim

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	6
Introduction	1
Aim of the Work.....	5
Review of Literature	
📖 Epidemiology	6
📖 Pathogenesis.....	8
📖 Diagnosis	16
📖 Treatment and Prognosis	20
Patients and Methods	32
Results	38
Discussion	67
Limitations	73
Conclusion and Recommendations.....	74
Summary	75
References	77
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Immunohistochemical features of GIST	14
Table (2):	PCR primers used for amplification and sequencing of KIT and PDGFRA exons	15
Table (3):	The molecular classification of GISTs	15
Table (4):	Risk of recurrence of GISTs according to the armed force institute of pathology Miettinen criteria	31
Table (5):	ECOG Performance Status	33
Table (6):	Baseline patient characteristics.....	39
Table (7):	Disease characteristics.....	40
Table (8):	Cases treated with Imatinib.....	47
Table (9):	Imatinib toxicity	48
Table (10):	Incidence of recurrence	50
Table (11):	Incidence of recurrence with different primary sites	51
Table (12):	Incidence and sites of recurrence	52
Table (13):	Outcome of treatment	53
Table (14):	OS	54
Table (15):	Time to progression	55
Table (16):	Correlation of overall survival with age is indirectly proportionate	56
Table (17):	Relation of overall survival with gender.....	57
Table (18):	Relation of overall survival with the site of tumor.....	58

List of Tables (Cont...)

Table No.	Title	Page No.
Table (19):	Relation of overall survival with presence of metastasis at time of diagnosis	59
Table (20):	Relation of overall survival with the size of the tumor.....	60
Table (21):	Relation of overall survival with the mitotic count of tumor cells.....	61
Table (22):	Relation of overall survival with the histopathological findings of the tumor	62
Table (23):	Relation of overall survival with recurrence.....	63
Table (24):	Relation of overall survival with different outcomes.....	64
Table (25):	The relation of anemia with OS.....	65
Table (26):	The relation of hypertension with OS.....	65

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Pathway of interstitial cell of Cajal maturation and GIST formation.....	8
Fig. (2):	Interstitial cells of Cajal	9
Fig. (3):	Mesoderm	9
Fig. (4):	Schematic structures of KIT and PDGFR.	10
Fig. (5):	Common histologic al features of GISTs.....	12
Fig. (6):	A gastric GIST with a nodular surface and thin capsule.....	12
Fig. (7):	Immunohistochemical features of GIST.	13
Fig. (8):	Computed tomography scan revealed a partially exophytic, dumbbell shaped solid mass (arrow) arising from the posterior aspect of the gastric fundus along the greater curvature, measuring approximately 6.7 cm × 4.5 cm.....	17
Fig. (9):	Duodenal GIST in a 52-year-old man presenting as a large intra-abdominal solid-cystic mass with central necrosis and heterogeneous enhancement on CT scan	18
Fig. (10):	A submucosal tumor in the gastric fundus.....	18
Fig. (11):	Fluorodeoxy glucose positron emission tomography (FDG-PET) scan showing response of metastatic gastrointestinal stromal tumor to imatinib mesylate	19
Fig. (12):	Gastric surgery.....	21
Fig. (13):	Wedge resection	21
Fig. (14):	Resection anastomosis of small intestine	22

List of Figures cont...

Fig. No.	Title	Page No.
Fig. (15):	Colon Resection.....	22
Fig. (16):	Glivec 400mg	24
Fig. (17):	Sutent 50mg.....	27
Fig. (18):	Stivarga 40mg	28
Fig. (19):	Percentages of males and females.....	42
Fig. (20):	Frequency of different symptoms present at diagnosis.....	42
Fig. (21):	Percentages of different sites of GIST.	43
Fig. (22):	Percentage of cases with liver metastasis.	43
Fig. (23):	Size of GIST.	44
Fig. (24):	Mitotic count of GIST cells.	44
Fig. (25):	Percentages of different histopathological types.	45
Fig. (26):	Presence of free margins.....	45
Fig. (27):	Percentages of different IHC.	46
Fig. (28):	Percentage of cases treated with Imatinib.	47
Fig. (29):	Number and percentage of cases with Imatinib toxicity.	48
Fig. (30):	Incidence of recurrence.	50
Fig. (31):	Incidence of recurrence with different primary sites.....	51
Fig. (32):	Incidence and sites of recurrence.....	52
Fig. (33):	Outcome of treatment.....	53
Fig. (34):	Survival.	54

List of Figures cont...

Fig. No.	Title	Page No.
Fig. (35):	Time to progression.....	55
Fig. (36):	Relation of overall survival with gender	57
Fig. (37):	Relation of overall survival with performance status at time of diagnosis.	58
Fig. (38):	Relation of overall survival with presence of metastasis at time of diagnosis.	59
Fig. (39):	Relation of overall survival with the size of the tumor.....	60
Fig. (40):	Relation of overall survival with the mitotic count of tumor cells.....	61
Fig. (41):	Relation of overall survival with the histopathological findings of the tumor.....	62
Fig. (42):	Relation of overall survival with the occurrence of recurrence.	63
Fig. (43):	Relation of overall survival with different outcomes.....	64
Fig. (44):	Relation of anemia with OS.....	65
Fig. (45):	Relation of hypertension with OS.....	66

List of Abbreviations

<i>Abb.</i>	<i>Full term</i>
<i>3D</i>	<i>3 Dimensions</i>
<i>AFIP</i>	<i>Armed Force Institute of Pathology</i>
<i>ASUH</i>	<i>Ain Shams University Hospitals</i>
<i>CD117</i>	<i>Cluster of Differentiation 117</i>
<i>CrCL</i>	<i>Creatinin Clearance</i>
<i>CT</i>	<i>Computerized Tomography</i>
<i>CTV</i>	<i>Clinical Target Volume</i>
<i>DDI</i>	<i>Drug-Drug Interaction</i>
<i>DNA</i>	<i>Deoxyribonucleic Acid</i>
<i>DOG-1</i>	<i>Discovered on GIST-1</i>
<i>ECG</i>	<i>Electrocardiography</i>
<i>ECOG</i>	<i>Eastern Cooperative Oncology Group</i>
<i>EORTC</i>	<i>European Organization for Research and Treatment of Cancer</i>
<i>ESMO</i>	<i>European Sarcoma Network Working Group</i>
<i>EUS</i>	<i>Endoscopic Ultrasound</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>GISTs</i>	<i>Gastrointestinal Stromal Tumors</i>
<i>HPF</i>	<i>High Power Microscope Fields</i>
<i>HTN</i>	<i>Hypertension</i>
<i>HU</i>	<i>Hounsfield Unit</i>
<i>ICC</i>	<i>Interstitial Cells of Cajal</i>
<i>IHC</i>	<i>Immunohistochemistry</i>
<i>IMRT</i>	<i>Intensity Modulated Radiotherapy</i>
<i>IQR</i>	<i>Interquartile range</i>
<i>MDT</i>	<i>Multi Disciplinary Team</i>
<i>MRI</i>	<i>Magnetic Resonance Imaging</i>
<i>NCCN</i>	<i>National Comprehensive Cancer Network</i>
<i>NCI</i>	<i>National Cancer Institute</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>OS</i>	<i>Overall Survival</i>
<i>PCR</i>	<i>Polymerase Chain Reaction</i>
<i>PET</i>	<i>Positron Emission Tomography</i>
<i>PFS</i>	<i>Progression Free Survival</i>
<i>PPI</i>	<i>Proton Pump Inhibitors</i>
<i>PTV</i>	<i>Planning Target Volume</i>
<i>R</i>	<i>Linear Correlation Coefficient</i>
<i>RECIST</i>	<i>Response Evaluation Criteria in Solid Tumors</i>
<i>SDH</i>	<i>Succinate Dehydrogenase</i>
<i>TKI</i>	<i>Tyrosine Kinase Inhibitor</i>
<i>US</i>	<i>United States</i>
<i>VEGFRs</i>	<i>Vascular Endothelial Growth Factor Receptors</i>

ABSTRACT

Background: GIST is classified into mutation in either KIT or cluster of differentiation 117 (CD117) oncogene (85%), Platelet – driven growth factor receptor alpha gene (PDGFRA) (10%) or rarely B-Raf gene. C.Kit - which is mutated & activated in 80% of GIST- is an oncogene which encodes cell surface receptor Tyrosine Kinase TK (CD117) which is responsible for activation of multiple signaling cascades leading to cellular proliferation.

Aim of the Work: to explore the best management options of care for patients at Ain Shams University Hospitals (ASUH) by retrospectively analyzing epidemiological factors in Gastrointestinal stromal tumor patients and correlate them to clinical outcome; these factors are either patient or disease ones, while outcome include clinical benefits, survival and encountered toxicities.

Patients and Methods: this is a retrospective study. This study included 34 patients with GIST treated at the department of Clinical Oncology and Nuclear medicine, Ain Shams University between 2011 -2017 and followed up till 1-2017.

Results: many prognostic factors were selected for analysis to evaluate their impact on overall survival. Age, gender, site and size of tumor, mitotic index, histopathology, presence of metastasis at time of presentation and anemia all had no statistically significant impact on overall survival.

Conclusion: the prognosis of GIST is undoubtedly better than other sarcomas. No clear risk factor of GIST. Patient selection is paramount as to minimize the high cost of treatment. Tumor density must be known by Hounsfield unit before treatment to detect pseudo progression. Molecular analysis by PCR is very important to know sensitivity to treatment as a predictive biomarker. Patients should be kept on follow up for early detection of recurrence.

Keywords: *Epidemiology - Gastrointestinal Stromal Tumour - cluster of differentiation 117*

Introduction

Gastrointestinal Stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract (GIT) i.e. sarcoma. The term GIST was first introduced by ***Mazur and Clark in 1983*** to describe non-epithelial tumors of the GI tract originating from pacemaker of smooth muscles (Interstitial Cells of Cajal (ICC)), stomach being the most common site (60%) with the best prognosis (***Demetri, 2011***).

GIST is classified into mutation in KIT also known as cluster of differentiation 117 (CD117) oncogene (85%), Platelet – driven growth factor receptor alpha gene (PDGFRA) (10%) or rarely B-Raf gene (***Miettinen and Lasota, 2006***). C.Kit - which is mutated & activated in 80% of GIST- is an oncogene which encodes cell surface receptor Tyrosine Kinase TK (CD117) which is responsible for activation of multiple signaling cascades leading to cellular proliferation (***Harding and Tap, 2014***).

The epidemiologic data being collected are not precise and the proportion between benign and malignant is not clear e.g. 5000 new cases per year in United States, 30 new cases per-million per year in Sweden. On the data base of the European Organization for Research and Treatment of Cancer (EORTC) study collected from 14 countries the incidence was 4-5 cases per million per year, 20-30% of which were inoperable and metastatic (***Cichoz-lach et al., 2008***)

In Egypt GIST represents 2.5% of gastrointestinal tumors. The majority of cases are at the age of 50-70 years being rare before the age of 40 years and the incidence is almost similar among men & women (*Mokhtar et al., 2007*).

Anatomic sites of GIST are stomach 60%, small intestine 30%, rare sites are large intestine, oesophages and mesentery. Clinical presentation is not characteristic e.g. abdominal pain, melena early satiety and weight loss. It may be asymptomatic and discovered incidentally during endoscopy, radiologic diagnostics or surgical intervention (*Harding and Tap, 2014*).

Diagnosis is made with endoscopic guided biopsy or after surgical resection, investigated by a pathologist under the microscope identifying spindle cell (75%) or epithelioid cell (25%) to suspect GIST and then confirmed by immunohistochemistry (IHC). C.KIT (CD117) is being positive in 90% and Vimentin being positive in mesenchymal cells. In case C.KIT is negative, recently a newer antibody DOG1 (Discovered on GIST) can be used in suspicious tumors (*Caram and Chugh, 2013*).

Radiologic imaging e.g. computerized tomography (CT) or magnetic resonance imaging (MRI) with contrast is used to locate site of lesion, evaluate signs of invasion and detect metastasis e.g. liver. In CT images large GISTs appear as heterogeneous masses due to areas of tumor cells, bleeding and necrosis. In small GISTs, images show smooth, well defined intramural masses with homogeneous attenuation (*Hersh et al., 2005*).

Prognosis depends on size and location of tumor and mitotic rate per 50 high power microscope fields (HPF). Size of at least 5cm is associated with good prognosis, while size more than 10cm is associated with high recurrence rate. Mitotic rate less than 5 per 50 HPF is associated with good prognosis while mitotic rate more than 5 is associated with high recurrence rate (*Cichoz-lach et al, 2008*).

Surgical resection is the main line of treatment in resectable and locally advanced diseases with 5 years survival rate up to 60% (*Hrycek et al., 2005*). Complete resection with negative margins is the goal. Lymphadenectomy is not required due to rare metastasis to lymph nodes. Laparoscopic surgery has been shown to be effective (*Nguyen et al., 2006*). Chemotherapy is not effective (*Kantarjian et al., 2011*).

Metastasis to liver is the most common, and can be treated by ablation (destructing tumour using extreme heat) or embolization (blocking the blood flow to cancer cells) (*National Comprehensive Cancer Network (NCCN), 2017*).

Imatinib (Glivec) is an oral tyrosine kinase inhibitor (TKI) which targets both C.KIT and PDGFR α proteins leading to decreasing the tumor cell growth. It can be used as an adjuvant therapy or neo-adjuvant to shrink the tumor preoperatively and in advanced GIST. The initial administration of this drug could lead to internal bleeding due to fragile blood vessels, so physicians must follow patients